The haptenation theory of vitiligo and melanoma rejection: a close-up
In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)
A pilot clinical trial investigating underlying mechanisms of semaglutide therapy in heart failure patients
It is clear that glutathione can be a benefit to your well-being, but how can you make the most of it
Get started with an initial consultation where we will review your medical history
Pick Agefine for daily maintenance, the others for diagnosed pigmentation issues